(D) Histogram illustrating changes in protein levels of pTau (T181), pTau (S262), PHF-1, total tau, GSK-3, CDK5, and p25 after treatment with tau kinase inhibitors in palmitoyl-L-carnitine-treated SH-SY5Y cells, shown as mean standard error of the mean (SEM
All content is provided for educational and research purposes only
The typical dosing schedule of the medication is as follows: 1 mg once weekly for the first 4 weeks 2 mg once weekly for the next 4 weeks 4 mg once weekly for the next 4 weeks if tolerated by the patient 8 mg once weekly for the next 4 weeks if tolerated by the patient 12 mg once weekly if tolerated by the patient, which is the maximum dosage
Request a certificate of analysis (COA) for the raw material
The study looked at those who quit within less than three months, and those who discontinued between the three-month mark and one year
301, F355F363